BI Asset Management Fondsmaeglerselskab A S Trims Position in Gilead Sciences, Inc. $GILD

BI Asset Management Fondsmaeglerselskab A S decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 32.5% during the first quarter, Holdings Channel reports. The fund owned 306,156 shares of the biopharmaceutical company’s stock after selling 147,311 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Gilead Sciences were worth $42,669,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of GILD. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC lifted its stake in shares of Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares during the period. Quattro Advisors LLC purchased a new position in shares of Gilead Sciences in the fourth quarter worth approximately $26,000. Wealth Preservation Advisors LLC grew its position in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares during the period. Finally, Ares Financial Consulting LLC bought a new stake in Gilead Sciences during the fourth quarter valued at approximately $28,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

NASDAQ GILD opened at $123.76 on Friday. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29. The stock has a market cap of $153.66 billion, a price-to-earnings ratio of 16.86 and a beta of 0.31. The company’s 50 day moving average is $131.66 and its two-hundred day moving average is $134.21. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences’s payout ratio is 44.69%.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the transaction, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at $21,524,408.40. The trade was a 1.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 68,000 shares of company stock valued at $8,930,150. Company insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent research reports. The Goldman Sachs Group increased their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research report on Wednesday, May 20th. Leerink Partners reduced their price objective on Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Morgan Stanley decreased their target price on Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research report on Monday, February 23rd. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $158.41.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.